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ABSTRACT 
Highly active antiretroviral therapy (HAART) is currently the only treatment that effectively 
reduces the morbidity and mortality of individuals infected with Human Immunodeficiency 
Virus-1 (HIV-1). Standard HAART regimens typically comprise 2 nucleoside reverse 
transcriptase inhibitors and either one non-nucleoside reverse transcriptase inhibitor or a protease 
inhibitor. These drugs bind to and inhibit the HIV-1 Reverse Transcriptase and Protease enzymes 
respectively, thereby suppressing viral replication. 
The nucleoside reverse transcriptase inhibitors promote mitochondrial (mt) dysfunction by 
strongly inhibiting mt polymerase gamma (Pol-y) and subsequently, mtDNA replication. In 
contrast, the non-nucleoside reverse transcriptase inhibitors, efavirenz (EFV) and nevirapine 
(NVP) do not inhibit Pol-y although EFV has been shown to induce mt depolarisation (Av|/mlow) 
in vitro at supra-therapeutic concentrations. However, the capacity of non-nucleoside reverse 
transcriptase inhibitor drugs to induce mt toxicity in vivo previously remained undetermined. The 
objective of this study was to determine the influence of EFV and NVP on peripheral lymphocyte 
mt transmembrane potential (Avj/m) and apoptosis in HIV-1-infected patients treated with these 
non-nucleoside reverse transcriptase inhibitors. 
Thirty-two HIV-1-infected patients on HAART between 4 and 24 months (12 on EFV, 20 on 
NVP) and 16 HAART-naive HIV-1-infected patients were enrolled into this study. All 
participants were black South African patients. Spontaneous peripheral lymphocyte apoptosis and 
Avj/m ow were measured ex vivo by flow cytometry for all patients. 
i 
CD4 T-helper apoptosis for the EFV and NVP cohorts was 19.38% ± 2.62% and 23.35% ± 
1.51% (mean ± SEM), respectively, whereas total lymphocyte A\|/m'ow was 27.25% ± 5.05% and 
17.04% ± 2.98%, respectively. Both parameters for each cohort were significantly lower (P < 
0.05) than that of the HAART-naive patients. The NVP cohort exhibited both a significant time 
dependent increase in peripheral lymphocyte A\|/mow (P = 0.038) and correlation between T-
helper apoptosis and A\|/mlow (P = 0.0005). These trends were not observed in the EFV cohort. 
This study provides evidence that both EFV and NVP induce peripheral lymphocyte A\|/m ow in 
HIV-1-infected patients on non-nucleoside reverse transcriptase inhibitor-based HAART, which 
in the case of NVP is sufficient to induce the apoptosis cascade. 
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The Human Immunodeficiency Virus (HIV) is the aetiological agent of the acquired 
immunodeficiency syndrome (AIDS). Infection with either HIV-1 or HIV-2 leads to immune 
compromisation with the onset of opportunistic infections and development of AIDS-related 
diseases. However HIV-1 is the primary cause of the present global AIDS pandemic. As at 
December 2007, approximately 33.2 million people worldwide were living with HIV-1. During 
2007 alone, there were approximately 2.5 million new infections and 2.1 million AIDS-related 
deaths worldwide (UNAIDS-WHO 2007). 
At present, 68% and 90% of the world's HIV-1 infected adults and children respectively live in 
Sub-Saharan Africa, with 76% of the total AIDS-related deaths in 2007 occurring in this region. 
AIDS is the single largest cause of mortality in Sub-Saharan Africa, making this region the most 
seriously affected by HIV. The majority of adults in Sub-Saharan Africa that are infected with 
HIV-1 are women (prevalence of 61%), a characteristic unique to this region (UNAIDS-WHO 
2007). South Africa currently has the largest number of HIV-1 infections in the world, the HIV-1 
prevalence being highest in the KwaZulu-Natal province (39%) (Department of Health South 
Africa, 2007). 
To date numerous multi-national attempts at producing an effective vaccine against HIV-1 have 
been unsuccessful. The treatment of HIV-infected patients with anti-retroviral (ARV) drugs 
currently remains the only effective method of retarding the progression of HIV-1 infection to 
AIDS. ARV drugs are typically administered as a "cocktail" of three drugs which constitutes 
highly active anti-retroviral therapy (HAART). When managed correctly, HAART is highly 
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effective in reducing the morbidity and mortality of individuals infected with HIV-1. However, 
despite dramatically improving the prognosis of patients infected with HIV-1, HAART remains 
ineffective in eradicating the virus from an individual once infected. Of the estimated 5.5 million 
South Africans that are already infected with HIV-1, approximately 1 million individuals 
presently require ARV therapy, of which only about 300000 are receiving it. In light of this 
statistic, the South African National AIDS Council adopted a decisive AIDS management 
strategy only in April 2007 to tackle the South African epidemic. This strategy set two main 
objectives to be achieved by the end of 2011, these being, firstly to halve the national infection 
rate and secondly, to increase the accessibility of ARV therapy to 80% of the infected individuals 
that require it. 
The high cost of ARV drugs, poor heath care infrastructure and lack of trained doctors and nurses 
presents major impediments to the successful implementation of HAART in South Africa's rural 
regions. Furthermore, the need for HIV-1 infected patients to be on life-long HAART together 
with the narrow therapeutic range of ARV drugs predisposes these patients to the risk of 
developing short- and long-term adverse toxic side-effects. Of even greater concern is the 
emergence of drug-resistant viral mutants that arise during patient-initiated treatment 
interruptions. These are the potential dire consequences of HAART when it is not monitored 
stringently. This emphasises the need for ARV drug rollout programmes to be coupled with 
efficient mechanisms to ensure patient adherence to HAART regimens and to closely monitor 




1.1 THE HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) 
1.1.1 THE HIV-1 GENOME 
HIV-1 and its subtypes are retroviruses and belong to the family of lentiviruses. The HIV-1 
genome is a 9.2 kilobase (kb) single-stranded (ss) positive (+) RNA molecule. HIV-1 virions 
contain two copies (dimers) of genomic (g) ssRNA, which upon infection are integrated as 
double-stranded (ds) DNA proviruses into the host cell genome. The organisation of the HIV-1 
genome is typical of retroviruses: 5V LTR-gag-pol-env-LTR 3X (LTR: Long Terminal Repeat; 
gag: Group Antigen; pol: Polymerase; env: Envelope) (Fig. 1.1). 
The LTRs are transcription regulatory sequences that flank either end of the protein-coding 
sequence and are each subdivided into three regions designated U3, R and U5 [1]. The U3 region 
contains binding sites for cellular transcription factors such as Nuclear Factor-kappa B (NF-KB) 
[2, 3]. The R region contains the trans-activation response element (TAR) to which Tat protein 
binds and maintains high transcription levels of the proviral dsDNA [4, 5]. The U5 region 
contains a binding site for transfer RNA lysine 3 (tRNALys3) [1], which acts as a primer for the 
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Figure 1.1. Organisation of the HIV-1 genome (HXB2 strain). The position of the start and stop codons of each gene are designated by 
numbers at the top left and bottom right corners respectively of the gene boxes. The reading frame of each gene is indicated to the left side 
of the diagram. The spliced exons of the tat and rev genes are indicated by shaded boxes. The position of the pol start codon (2085) is 
shifted -1 relative to the start codon of gag-pl (2086) [7]. 
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The sequence between the U5 region and the gag AUG start codon contains the 5' leader domain, 
consisting of the primer binding site (PrBS), dimer initiation site (DIS) and packaging signal (v|/) 
[8, 9]. These regions adopt secondary and tertiary structures that divert the viral mRNA strand 
from translation and into packaging as gRNA dimers in assembling virions [10, 11]. 
The gag region encodes the major structural proteins of the virus, pl7 Matrix (MA), p24 Capsid 
(CA), p7 Nucleocapsid (NC) and p6, which are initially translated as a single p55 Gag 
polyprotein precursor [12]. The pol gene is located immediately downstream from the gag gene, 
with its reading frame shifted -1 relative to that of gag (Fig. 1.1, frame 3). The Protease (PR), p51 
Reverse Transcriptase (RT), pi5 RNase H and p31 Integrase (IN) enzymes are encoded by the 
pol gene. The env region encodes the gpl20 and gp41 proteins which are involved in recognising 
and attaching to the host cell. The HIV-1 genome also encodes the genes of the regulatory (tat 
and rev) and accessory (vif, vpr, vpu and nef) proteins, whose reading frames are indicated 
relative to the gag, pol and env genes (Fig. 1.1). 
1.1.2 GENETIC VARIANTS OF HIV-1 
HIV-l is comprised of three major groups, designated M (main), O (outlier) and N (non-M non-
O). Group M is further sub-divided into 9 clades or subtypes (A-D, F-H, J and K). The subtypes 
are classified and distinguished from each other on the basis of phylogenetic analysis of full 
length viral genomes, with each subtype represented by its own consensus sequence [13]. 
Subtype C accounts for 50% of the HIV-1 infections worldwide and is the most prevalent 
subtype in China, India and Central, Eastern and South Africa [14]. Subtypes A, B, G and D 
5 
represent 12, 10, 6 and 3% respectively of the total worldwide prevalence of HIV-1 group M, and 
subtypes F, H, J and K account for approximately 1% [14]. 
The remaining 18% of group M is represented by circulating recombinant form (CRF) viruses 
[14]. The CRFs are viruses whose genomic sequences are recombinants (mosaics) of more than 
one phylogenetic subtype and are common in geographic regions with a high prevalence of more 
than one viral subtype. To date 43 group M CRFs have been identified [15]. Inter-subtype 
recombination occurs when a host cell is productively super-infected with two distinct viral 
subtypes, with the gRNA strands of each subtype being compatible to form heterodimers during 
viral packaging [16]. Following infection, the viral genomic ssRNA is reverse transcribed into 
dsDNA, during which HIV-1 RT frequently switches between the two packaged copies of viral 
gRNA templates [17], a process known as copy choice [18]. The switching of RT between 
heterozygous RNA strands during multiple-subtype super-infection [19], results in the synthesis 
of recombinant proviral DNA [20]. If the new recombinant proviral genome confers enhanced 
immune evasion [21, 22] and/or anti-retroviral (ARV) drug resistance [23], the virus is then 
transmitted as a CRF. 
1.1.3 VIRAL ULTRASTRUCTURE 
Mature HIV-1 virions have a spherical morphology and range between 100 - 120nm in diameter. 
A lipid bilayer envelope, of host cell origin, encapsulates the virion into which approximately 72 
Env-glycoprotein complexes are integrated. Each complex is a trimer of the non-covalently 
linked external-gpl20 and transmembrane-gp41 heterodimer [24, 25] (Fig. 1.2B). The gpl20 
moiety contains binding sites for the CD4-ligand and chemokine co-receptor (CCR5 or CXCR4), 
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the latter formed by the VI/V2 and C4 regions and V3 loop [26]. GP41 contains the HR1 and 
HR2 helices and hydrophobic fusion peptide that penetrates and anchors the virion into the host 
cell membrane [27, 28]. Host cell receptors such as Human Leukocyte Antigen (HLA) class I and 
II are also incorporated into the viral envelope during budding [29]. 
MA (pi7) proteins form a shell lining the inner surface of the viral envelope through the 
interaction of the N-myristylated terminal of MA with the host membrane cytoplasmic leaflet 
[30]. The hollow viral conical core is produced from the assembly of CA (p24) proteins into 
hexameric rings [31]. The capsid core contains two copies of viral ssRNA in complex with NC 
protein and RT and IN enzymes [32] (Fig. 1.2B). The aspartyl protease (PR), tRNALys3 [6, 33] 
and p6 [34], vpr [35], vif [36] and nef [37] proteins are also packaged within the capsid core (Fig. 
1.2B). 
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Figure 1.2. Schematic diagrams of the immature (A) and mature (B) HIV-1 virion [38]. The 
immature virion notably lacks a capsid core, with the structural and enzymatic proteins still 
contained as part of the Gag and GagPol polyproteins. The virion attains maturity and is rendered 
infectious upon PR-mediated auto-catalytic cleavage of Gag and GagPol polyproteins. 
8 
1.1.4 HOST CELLS 
The CD4 ligand, a 58kDa monomelic glycoprotein, is expressed on the surface of T-helper 
lymphocytes, bone marrow and thymic T-cell progenitors, monocytes and macrophages, dendritic 
and microglial cells [39]. CD4 is the primary receptor for HIV-1 [40, 41], whilst the chemokine 
receptors CCR5 [42-44] and CXCR4 [45] (G-protein-coupled 7-transmembrane receptors) are the 
major co-receptors utilised by HIV-1 in vivo. CXCR4 is mainly expressed on naive CD4+ T-
helper lymphocytes (THL), whereas activated memory CD4
+ THLs, monocytes and macrophages 
express CCR5 [46, 47]. Viruses that utilise either only CCR5 or only CXCR4 are designated R5-
and X4-tropic respectively, whilst viruses capable of utilising both co-receptors are designated 
R5X4 [48]. 
The most significant long-term cellular reservoirs of HIV-1 are memory CD4+ THL [49, 50] and 
macrophages [51], due to the long life span of these cells. Immature dendritic cells, such as 
Langerhans cells, present in the genital epithelium, also support the replication of HIV-1 and play 
an important role during the early stages of sexual transmission of the virus [52]. Furthermore, 
circulating and follicular dendritic cells are capable of trapping extracellular virions on their 
membrane processes [53], and upon interaction with CD4+ THLS in lymph nodes facilitate 
infection of these cells [54]. Epithelial dendritic cells express 10-fold more surface CCR5 than 
CXCR4 [55], and thus selectively propagate R5 strains [56]. HIV-1 R5 strains are preferentially 
transmitted via the sexual route [47] and predominate during the early stages of infection. The 
phenotypic switch from the R5 to the X4 or R5X4 strains in vivo generally occurs only several 
years after infection, which is accompanied by accelerated CD4+ THL loss and progression to 
AIDS [57]. In contrast to this observation, X4 viruses are far less frequent than R5 viruses in 
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individuals who are infected with subtype C HIV-1 [58]. The switch in viral tropism is 
determined by amino acid changes primarily in the V3 loop of gpl20 [59-61]. 
1.1.5 VIRAL LIFE CYCLE 
The viral life cycle is a series of 6 sequential stages: 1) viral attachment and entry, 2) reverse 
transcription, 3) integration, 4) transcription, 5) translation, 6) viral assembly, budding and 
maturation. The initial binding event between the viral particle and host cell is the interaction of 
gpl20 with the host cell CD4 receptor. GP120-CD4 binding induces a conformational change in 
gpl20 that exposes its chemokine co-receptor binding site [62], with subsequent binding to either 
CCR5 or CXCR4. Co-receptor recruitment in turn triggers the insertion of the gp41 hydrophobic 
fusion peptide [63] into the host cell membrane thereby inducing the HRl and HR2 domains of 
gp41 to adopt a stable six-helix bundle structure [64]. The viral envelope and host cell membrane 
then fuse delivering the p24 capsid core into the host cell cytoplasm where it is subsequently 
disassembled. 
Capsid disassembly (viral uncoating) releases the dimeric gRNA which is reverse transcribed into 
dsDNA by the viral RT enzyme [65]. The preintegration complex (PIC), a complex of linear 
dsDNA with IN, MA, NC, PR, RT, and Vpr proteins [32, 66], is transported along microtubules 
[67] towards the nucleus. Active transport of the PIC across the nuclear pore complex [68] into 
the nucleus is mediated by MA and Vpr [69-71], a feature that allows HIV-1 to replicate in 
interphasic or quiescent cells [72]. Productive infection is achieved when the viral linear dsDNA 
is integrated, as the provirus, into the host cell genome by viral IN [73]. Viral transcription is 
activated by the binding of cellular factors, such as NFKB, to the proviral LTR [74]. Multiple-
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spliced mRNAs are initially produced from which the regulatory proteins, Tat, Nef and Rev, are 
expressed. Rev promotes the accumulation of non-spliced or singly-spliced mRNAs [75] which 
are directed to cytoplasmic polysomes [76] for translation or packaging as gRNA dimers. 
P55 Gag, GagPol and gpl60 are the predominant viral proteins synthesised during the late stages 
of the viral replication cycle. Following glycosylation in the endoplasmic reticulum, gpl60 is 
cleaved in the Golgi apparatus by cellular proteases into the gpl20 and gp41 subunits [77], which 
are subsequently inserted into the plasma membrane. The PR, RT, RNase H and IN enzymes are 
derived from the GagPol polyprotein. Gag and GagPol are synthesised in an approximately 20:1 
ratio, the latter produced following a -1 ribosomal frameshift during translation [78]. 
Viral particles are assembled from the oligomerisation of Gag and GagPol polyproteins under the 
host cell membrane [31, 79] (Fig. 1.2A). Viral assembly and budding is mediated via three 
specific domains of p55 Gag polyprotein precursor, designated the M (membrane targeting), I 
(interaction) and L (late assembly) domains. The N-myristylated terminal in the MA (M) domain 
of p55 Gag facilitates the insertion of Gag into the host plasma membrane [80, 81]. The NC (I) 
domain of p55 Gag chaperones the dimerisation of viral ssRNA [82, 83] via its two zinc-finger 
motifs [84, 85] and also facilitates the switch of newly synthesised viral mRNA to gRNA [11, 
86]. This directs the packaging of viral RNA into progeny virions. The I-domain also mediates 
Gag-Gag interactions at the plasma membrane [79, 87]. The p6 (L) domain mediates viral 
budding [88] and promotes the incorporation of Vpr into the assembling virions [89]. The 
budding viral particle composed of Gag and GagPol precursors (Fig. 1.2A) is immature and non-
infectious. During budding, viral PR cleaves the Gag and GagPol polyproteins into their 
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individual structural protein and enzymatic components (Fig. 1.2B), which is essential for viral 
maturation and viral budding to occur with maximum efficiency [90]. 
1.2 THE PATHOGENESIS OF HIV-1 
The hallmark feature of HIV-1 - infected patients is a progressive decline in their CD4+ THL and 
to a lesser degree, CD8+ cytotoxic T-lymphocyte (CTL) levels, resulting in immunodeficiency 
which renders the patient susceptible to opportunistic infections and malignancies. The primary 
mechanism of T-cell depletion during HIV-1 infection is elevated CD4+ THL and CD8+ CTL 
apoptosis [91-95]. Rapid disease progression has been shown to correlate with both elevated 
patient viral load [96] and CD4+ THL apoptosis [97] levels, whilst the latter correlates inversely 
with CD4+ THL counts [98]. Paradoxically, the majority of CD4
+ THL cells undergoing apoptosis 
are uninfected by HIV-1 [99]. 
1.2.1 APOPTOSIS 
Apoptosis is a controlled energy-dependant, physiological death process that maintains cellular 
homeostasis in multicellular animal organisms by removing individual unwanted as well as 
aberrant and virus-infected cells, whilst maintaining the integrity of adjoining cells. Apoptotic 
cells are morphologically distinguishable from normal cells by the appearance of chromatin 
condensation, nuclear fragmentation, plasma membrane blebbing and cell shrinkage that 
ultimately results in cellular fragmentation into smaller membrane-bound vesicles (apoptotic 
bodies) [100, 101]. The regulated biochemical and morphological disintegration of an apoptotic 
cell is executed by the class of proteolytic enzymes known as caspases. 
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1.2.1.1 CASPASES 
Caspases (cysteine-dependant aspartate-specific proteases) [102] are highly specific proteases 
which catalyse a cysteine (Cys)-mediated hydrolysis of peptide bonds that immediately follow 
aspartate (Asp) residues [103]. Initially synthesised as inactive single chain proenzymes 
(zymogens), procaspases are activated by proteolytic cleavage at two Asp sites flanking the linker 
segment that separates the large (17-20kDa) and small (9-12kDa) subunits [103, 104]. The active 
caspase is a heterotetramer of two large and two small subunits [105-107]. This mechanism of 
activation facilitates the recruitment of latent procaspases in an amplifying proteolytic cascade 
[108-110]. Caspases involved in apoptosis belong to two classes based on their point of action in 
the caspase cascade: (a) the initiators, subdivided into the intrinsic (caspase-9) and extrinsic 
(caspases-2, -8 and -10) apoptosis pathway activators, and (b) effectors (caspases -3, -6 and -7) 
[111,112]. 
Initiator caspases possess autocatalytic activity i.e. the ability to auto-activate [113]. However, 
autocatalytic activation of the initiator caspases occurs only upon recruitment and oligomerisation 
[114, 115] of several procaspase-2/8/10 and procaspase-9 molecules to either the cell surface 
death receptors (extrinsic pathway) or apoptosome (intrinsic pathway) respectively. The death 
effector domains (DED) [116, 117] and caspase recruitment domains (CARD) [118] are located 
in the long N-terminal peptides of procaspase-8/-10 and procaspases-2/-9 respectively. These 
domains mediate the targeting and association of the intrinsic and extrinsic initiator caspases with 
the complementary DEDs of the death receptor or CARD of the apoptosome respectively [108, 
119]. Once activated, the initiator caspases cleave and activate the downstream effector 
procaspases [120-122]. Both procaspases-3 and -7 can also be cleaved and activated directly by 
13 
granzyme-B [123] [proteases delivered into a cell via perforin (pore-forming proteins) channels 
inserted by natural killer cells and CTLs]. 
Effector caspases usually mediate only a single cleavage of a protein substrate which either 
activates or inactivates that protein [104]. A broad range of cellular substrates are cleaved by 
effector-caspases including apoptotic and survival signalling kinases (MEK kinase-1 [124], 
protein kinase C delta (PKC5) [125], phosphatidylinositol-3 kinase/Akt-1 and Raf-1 [126]), pro-
and anti-apoptotic BCL-2 family proteins (Bid [127], BCL-2 [128], BCL-XL [129]), structural 
proteins (nuclear lamins [123, 130], actin [131], a-fodrin [132, 133] and gelsolin [134]), the DNA 
repair protein poly (ADP-ribose) polymerase (PARP) [135] and the endonuclease CAD/ICAD 
[136, 137]. The translocation of phosphatidylserine (PS) from the inner plasma membrane leaflet 
to the outer leaflet early in apoptosis is also caspase dependant [138], which triggers the removal 
of the apoptotic cell by macrophages [139]. The inhibitor of apoptosis proteins (IAPs) XIAP, c-
IAP1 and C-AIP2, expressed in mammalian cells, bind directly to and inhibit active caspase-3 and 
-7 [140, 141]. 
During HrV-1 infection, lymphocyte apoptosis is mediated primarily via the death receptor 
(extrinsic) and/or mitochondrial (intrinsic) pathways. 
1.2.1.2 THE EXTRINSIC PATHWAY 
The cell surface transmembrane death receptors belong to the tumour necrosis factor (TNF) 
superfamily, and are characterised by cysteine-rich extracellular domains [142] and an 
intracellular cytoplasmic "death domain" (DD) sequence [143]. Death receptor-induced T-cell 
apoptosis in HIV-1 infected patients is mediated primarily by the ligation of Fas (CD95/APO!) 
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[144-147], TNFR1/2 [148-150] and TNF-related apoptosis-inducing ligand (TRAIL-R1/2) [151-
153] receptors by their respective cognate ligands (FasL, TNF and TRAIL/AP02L) (Fig. 1.3). T-
cells (THL and CTL) of HIV-1 infected patients exhibit increased expression of particularly Fas 
[154-157] and TNFR1 receptors [158-160] (including their cognate ligands), thus enhancing their 
susceptibility to Fas- and TNF-mediated apoptosis respectively. Both TNFR1 and TRAIL-R1/2 
receptors share similar mechanisms of caspase activation with the Fas receptor (Fig. 1.3). 
Upon binding of homotrimeric FasL, Fas receptors undergo trimerisation [161] resulting in the 
recruitment and aggregation of Fas-associated death domain (FADD) adapters [162] to the 
receptors' cytoplasmic domains. Fas/FADD interactions are mediated by the DD motifs located 
in both proteins [162-163]. FADD additionally contains an N-terminal DED motif that facilitates 
the recruitment of multiple procaspase-8 zymogens [117, 164] (via their DED motifs) to Fas. 
CAP-3 (cytotoxicity-dependant APO-1 associated protein), which contains a DED motif, is also 
recruited to FADD and functions in procaspase-8 recruitment [117]. This multi-protein complex 
is known as the death-inducing signalling complex (DISC) [165]. Oligomerisation at the 
membrane induces procaspase-8 auto-activation which in turn activates procaspase-3 zymogens 
[113-115]. The above pathway is distinctive of cells, such as the H9 cell line, that undergo 
apoptosis via the type-I Fas signaling pathway (Fig. 1.4). The type-I Fas pathway typically 
bypasses mitochondria leading directly to caspase activation. In type-II Fas cells, such as the 
Jurkat cell line, DISC formation is restricted which leads to mitochondrial permeabilisation and 
subsequent activation of caspases-8 and -3 downstream of mitochondria [166] (Fig. 1.4). 
Consequently, only type-II Fas-mediated apoptosis can be blocked by the over-expression of 
anti-apoptotic Bcl-2 and BC1-XL proteins, which inhibit mitochondrial permeabilisation [166]. 
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In TNF-mediated apoptosis the adapter molecule, TNFR-associated death domain (TRADD), 
facilitates the binding between the DDs of TNFR1 and FADD [167]. Upon receptor ligation, 
TRADD additionally recruits the secondary adapters RIP (receptor interacting protein) and 
TRAF2 (TNFR-associated factor 2) which both activate the NF-KB and JNK survival signalling 
pathways [168-170], thereby counteracting the apoptotic signal. Furthermore, HIV-1 induces the 
production and secretion of TNFoc by lymphocytes and peripheral blood mononuclear cells 
(PBMCs) [171]. TNFoc induces the autocrine activation of NFKB [172-173] which in turn binds 
to the HIV-1 LTR [3] thereby inducing transcription of the HIV-1 provirus [174] and further 
stimulating TNFoc production. 
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Figure 1.3. Schematic diagram of the intrinsic and extrinsic apoptosis induction pathways [175]. 
Signals from all pathways notably converge at the mitochondrion, culminating in the activation 


















Figure 1.4. Schematic overview of the Fas type I (A) and type II (B) pathways [166]. In type I 
cells, DISC formation predominates following Fas-FasL ligation leading directly to the activation 
of procaspase-8 and procaspase-3, independently of the mitochondria. In type II cells, DISC 
formation is limited and is characterised by mitochondrial PT followed by the release of 
cytochrome c into the cytoplasm and caspase activation. 
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1.2.1.3 THE INTRINSIC (MITOCHONDRIAL) PATHWAY 
The mitochondrion is the central organelle at which signals from numerous intracellular stresses 
converge, including calcium accumulation, reactive oxygen species (ROS), sphingolipids and 
DNA damage, resulting in mitochondrial outer membrane permeabilisation (MOMP) [176-178]. 
MOMP is induced by the opening of the permeability transition pore complex (PTPC). The 
PTPC, a transmembrane channel between the inner and outer mitochondrial membranes (IMM, 
OMM), is formed primarily by the interaction of VDAC (voltage-dependant anion channel) in the 
OMM with ANT (adenine nucleotide transporter) and cyclophilin D (CyP-D) in the IMM [179]. 
Opening of the PTPC is regulated by the pro- and anti-apoptotic BCL-2 (B-cell CLL/Lymphoma 
2) family of proteins (Fig. 1.3). The anti-apoptotic proteins include BCL-2, BCL-XL, BCL-W 
and MCL1, whilst the pro-apoptotic subfamily is subdivided into the pore-forming proteins (Bak 
and Bax) and BH3 domain-only proteins (BID, BAD, BIM, BIK, BMF, NOXA, PUMA and 
HRK) (Fig. 1.3). BCL-XL inhibits the opening of the PTPC by integrating into the OMM and 
binding directly to the VDAC [180], whilst Bax, Bak and BIM promote PTPC opening by 
binding to VDAC [181, 182]. Furthermore, MOMP is also induced upon homo-oligomerisation 
of Bax and Bak in the OMM [183, 184]. Bax can be directly activated by p53 tumour suppressor 
protein to induce MOMP [185], whilst both Bax and Bak homo-oligomerisation is induced by 
truncated BED (tBED) [184, 186, 187] (Fig. 1.3). Death receptor ligation results in caspase-8 
cleavage of cytosolic BID to tBED [127, 188, 189]. tBID also directly induces MOMP by forming 
homo-oligomer pores in the OMM [190] and thus relays apoptotic signals from the cell surface to 
the mitochondria (Fig. 1.3). 
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Following MOMP, small pro-apoptotic proteins, including cytochrome c [191], second 
mitochondria-derived activator of caspase/ direct IAP-binding protein with low pi (Smac/Diablo) 
and Omi/HtrA2 (IAP inhibitors)[192, 193], apoptosis-inducing factor (AIF) and endonuclease G 
(nucleases) [194, 195], are released from the mitochondrial intermembrane space into the cytosol. 
The release of cytochrome c is accompanied by the collapse of the mitochondrial inner 
transmembrane potential (Ai|/m) [196], known as permeability transition (PT) or depolarisation 
(Av|/mlow), which irreversibly commits the cell to apoptosis [197, 198]. In the cytosol, cytochrome 
c assembles with dATP, apoptotic protease-inducing factor-1 (Apaf-1) and procaspase-9 (the 
latter two interacting via their CARD motifs) to generate the apoptosome [199-201]. Formation 
of the apoptosome induces auto-catalytic activation of procaspase-9, which subsequently recruits 
and activates procaspase-3 [202] (Fig. 1.3). 
Peripheral circulating T-cells of HIV-1 infected patients are characterised by an increase in 
A\|/mlow [203], an event crucial to T-cell apoptotic death during AIDS [204]. The collapse of Av|/m 
and PS-externalisation are early apoptotic events both of which can be measured flow 
cytometrically on whole cells stained with the JC-1 and Annexin-V-FITC fluorophores 
respectively [205, 206]. 
1.3 ANTI-RETRO VIRAL DRUGS 
The an ti-retroviral (ARV) drugs currently licensed in South Africa (SA) for the treatment of 
HIV-1 infection target and inhibit the viral RT and PR enzymes, thereby retarding viral progeny 
synthesis. The ARV drug classes comprise the nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitor (NNRTIs) and protease 
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inhibitor (Pis). The co-administration of at least two NRTIs with either one NNRTI or PI 
constitutes highly active anti-retroviral therapy (HAART) and is now standard of care of HIV-1 
infected individuals [207]. HAART dramatically reduces plasma viral load with a concomitant 
increase in circulating CD4+ THLS [208-210]. However, HAART targets only actively replicating 
virus and is ineffective in eliminating dormant virus in reservoir and sanctuary sites [211]. This 
necessitates an HIV-1 infected individual to be on life-long HAART to maintain suppression of 
viral replication. Ex vivo studies have reported the persistence of T-lymphocyte apoptosis in 
patients undergoing HAART, particularly with NRTI-NNRTI based regimens [212, 213]. In 
addition to their anti-viral properties, NRTIs, NNRTIs and Pis modulate lymphocyte apoptosis at 
the level of the mitochondrion, which will be discussed further. 











Figure 1.5. Chemical structures of the NRTIs (nucleoside derivatives) [214] commonly 
prescribed in South Africa for the treatment of HIV-1 infection. 
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The NRTIs are dideoxyribonucleoside derivatives that lack a 3 -̂OH group on the deoxyribose 
sugar moiety. Within the cell, NRTIs are phosphorylated in a step-wise manner by various 
cellular kinases to their 5V-triphosphate derivatives (NRTI-TPs) [215-217]. Thymidine analogues 
are most efficiently phosphorylated in activated PBMCs, whereas ddl, 3TC and zalcitabine (ddC) 
are preferentially phosphorylated in resting PBMCs [218, 219]. The NRTI-TPs compete with 
endogenous deoxyribonucleotides for the catalytic site of RT. Incorporation of an NRTI-TP at the 
3v-end of the elongating viral DNA strand results in premature termination of reverse 
transcription [216, 220]. 
1.3.1.1 MITOCHONDRIAL TOXICITY OF THE NRTIs 
In light of their mechanism of action, NRTI-TPs also potentially compete as substrates for 
cellular DNA polymerases a, p, s and y [221]. However, mitochondrial DNA polymerase-gamma 
(Pol-y), the enzyme required for replication of mitochondrial DNA (mtDNA), is most potently 
inhibited by NRTI-TPs [221, 222]. The in vitro hierarchy of Pol-y inhibition by NRTI-TPs, in 
descending order, is as follows: ddC > ddl > d4T > 3TC > emtricitabine (FTC) > AZT > abacavir 
(ABC) [221]. Pol-y inhibition results in mtDNA depletion, which has been observed in vitro in 
NRTI-treated cell lines [223-225] and in vivo in fat [226, 227], skeletal muscle [228, 229] and 
liver tissue [230] of patients presenting with lipodystrophy syndrome (LDS). Whilst mtDNA 
depletion was reported in human peripheral lymphocytes exposed both in vivo [231, 232] and in 
vitro [233, 234] to NRTIs, individuals asymptomatic for LDS whilst undergoing HAART did not 
exhibit lymphocyte mtDNA depletion [235]. 
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mtDNA depletion results in decreased synthesis of mtDNA-encoded respiratory chain complex 
subunits [232, 233], which manifests predominantly during long-term HAART [236, 237]. This 
ultimately compromises oxidative phosphorylation resulting in increased anaerobic respiration 
and lactic acid production, culminating in elevated serum lactate levels (hyperlactatemia) [233, 
238-240]. AZT-induced respiratory chain dysfunction also increases the generation of ROS 
within the mitochondrion [241-243], resulting in apoptosis [244]. Cells lacking mtDNA undergo 
apoptosis via induction of PT [245] possibly as a result of ROS-mediated attack of the ANT 
and/or VDAC components of the PTPC, independent of pro-apoptotic Bcl-2 proteins [246, 247]. 
1.3.2 THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 
INHIBITORS 
Figure 1.6. Chemical structures of the NNRTIs [214] commonly prescribed in South Africa for 
the treatment of HIV-1 infection. 
NNRTIs are a heterogeneous class of small (<600Da) hydrophobic non-nucleoside analogue 
compounds that specifically inhibit HIV-1 RT, but not HIV-2 RT [248]. In contrast to NRTIs, 
NNRTIs do not require intracellular metabolism for activation. NNRTIs non-competitively 
inhibit reverse transcription by binding to the "NNRTI-binding pocket", located allosterically to 
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the substrate binding (DNA polymerase) site in the p66 subunit of HIV-1 RT [249, 250] (Fig. 
1.7). The NNRTI-binding pocket is spatially and functionally associated with the DNA 
polymerase site [251, 252] (Fig. 1.7), which upon binding a NNRTI drug locks the DNA 
polymerase site in an inactive conformation [253]. 
In addition, EFV (but neither NVP nor Delavirdine) enhances the intracellular proteolytic 
processing of Gag and GagPol polyproteins with a concomitant decrease in viral particle 
production [254]. This is mediated by the binding of EFV to RT embedded in the GagPol 
polyprotein thereby promoting the oligomerisation of GagPol polyproteins. This induces 
premature activation of the PR enzyme embedded within GagPol, and subsequent cleavage of the 
polyproteins into their constituent structural and enzyme subunits. As a result, this decreases the 
amount of full-length Gag and GagPol polyproteins that are necessary for viral assembly and 
budding from the host cell membrane [254]. 
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Figure 1.7. Ribbon representation of HIV-1 RT in complex with EFV (grey). The p66 and p51 
subunits of HIV-1 RT are coloured red and green respectively. Residues located in the DNA 
polymerase and RNase H active sites are indicated with yellow spheres [255]. 
1.3.2.1 MITOCHONDRIAL TOXICITY OF THE NNRTIs 
In contrast to the NRTIs, much less is known about the apoptosis-inducing potential of the 
NNRTIs and the mechanism/s thereof. EFV has been shown to induce apoptosis in vitro in both 
the Jurkat cell line and PBMCs, which were characterised by a dose-dependant increase in 
Av|/mlow, cytochrome c release, procaspase-9 and -3 activation and PS externalisation [256]. This 
finding suggests a mitochondrial mechanism of NNRTI-induced lymphocyte cytotoxicty, 
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however the precise mechanism of NNRTI-induced mitochondrial PT in lymphocytes remains 
unknown. 
NNRTIs appear to influence the expression of uncoupling proteins (UCPs) in brown adipocytes. 
UCPs are proton transporters, present in the IMM, that catalyse a regulated discharge of the 
proton gradient across the IMM i.e. reduction of the Ai|/m. UCPl is expressed exclusively in 
brown adipose tissue, UCP3 in brown adipose and muscle tissue, UCP 4 and BMCPl in the 
brain, whilst UCP2 expression is widespread [257]. In an in vitro study, both d4T and NVP 
significantly induced the UCPl mRNA expression in treated brown adipocytes, with the level of 
induction by NVP being significantly higher than by d4T [258]. Neither of these drugs influenced 
the expression of UCP2 mRNA, whilst EFV had no effect on the expression of UCPl and UCP2 
mRNA in brown adipocytes with respect to the control [258]. 
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Figure 1.8. Chemical structures of the Pis [214] commonly prescribed in South Africa for the 
treatment of HIV-1 infection. Other drugs in this class include Indinavir (IDV), Nelfinavir (NFV) 
and Saquinavir (SQV). 
The importance of HIV-1 PR in viral maturation lends itself as a potent target for the inhibition 
of viral replication. Pis are transition state peptidomimetic analogues that bind more tightly than 
the natural substrates to aspartate residues in the PR catalytic active site, thus competitively 
inhibiting the PR enzyme [214, 259]. Inhibition of HIV-1 PR results in the production of 
immature and non-infectious viral particles. 
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1.3.3.1 MITOCHONDRIAL PROTECTIVE EFFECT OF Pis 
Numerous studies reported that after initiation of Pi-containing HAART, patients exhibited 
marked increases in their circulating CD4+ THL counts before significant decreases in plasma 
viral RNA load [209, 260-262]. This has been attributed to the independent inhibition of 
lymphocyte apoptosis by PI drugs both ex vivo and in vitro [263, 264]. Phenix et al [265] 
reported that NFV inhibited Jurkat cell apoptosis within 1 hour of treatment, at clinically 
achievable concentrations, in the presence of apoptotic stimuli. NFV blocked PTPC opening at 
the level of the ANT and thus the collapse of Ai|/m and cytochrome c release in the presence of 
apoptotic stimuli, but did not inhibit active caspase-3, -6, -7, or -8 proteolytic activity [265]. NFV 
however did not inhibit Fas-mediated apoptosis in the type-I Fas H9 cell line [265]. The 
inhibition of ANT function in PTPC formation by NFV was also confirmed in another 
independent study [266]. 
Several studies subsequent to Phenix et al [265] reported the inhibition of Av|/mow and 
mitochondrial-driven apoptosis by protease inhibitors [267-270]. In addition, Matarrese et al 
[269] reported the novel finding that LPV, IDV and SQV reduced UCP2 protein expression, in a 
dose-dependant manner, in T-lymphocytes isolated from human PBMCs, with a concomitant 
reduction in mitochondrial PT and ROS production. Thus Pis maintain the integrity of the 
lymphocyte mitochondrial Aym by preventing opening of the PTPC and UCP-mediated 
discharge of the Av|/m. 
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CHAPTER 2 
SCIENTIFIC PAPER PUBLICATION 
PREFACE 
The following paper published in the Journal of Acquired Immune Deficiency Syndromes (48(4); 
August 2008, 381-388), documents the persistence of peripheral lymphocyte mitochondrial 
depolarisation and apoptosis in Black South African HIV-l infected patients undergoing HAART 
that contained either one of the NNRTIs, EFV or NVP. 
This study was undertaken in light of the lack of literature regarding the potential of the above 
NNRTIs to induce lymphocyte mitochondrial dysfunction and apoptosis in vivo. 
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BASIC SCIENCE 
Lymphocyte Mitochondrial Depolarization and 
Apoptosis in HIV-1-Infected HAART Patients 
Leshern Karamchand, MSc,* Halima Dawood, MD, FCP.f and Anil A. Chuturgoon, PhD* 
Background: Efavirenz (EFV) and nevirapine (NVP), unlike nucle-
oside reverse transcriptase inhibitor drugs, do not inhibit mitochon-
drial (mt) polymerase gamma (Pol--y), although EFV has been shown 
to induce mt depolarization (Ai|;m'ow) in vitro at supratherapeutic con-
centrations. However, the capacity of nonnucleoside reverse tran-
scriptase inhibitor drugs to induce mt toxicity in vivo remains 
undetermined. 
Object ive: To determine the influence of EFV and NVP on 
peripheral lymphocyte mt transmembrane potential (A«(<m) and 
apoptosis in HlV-1-infected patients treated with these nonnucleo-
side reverse transcriptase inhibitors. 
Methods: Thirty-two HIV-1-infected patients on highly active 
antiretroviral therapy (HAART) between 4 and 24 months (12 on 
EFV, 20 on NVP) and 16 HAART-naive HIV-1-infected patients were 
enrolled into this study. All participants were black South African 
patients. Spontaneous peripheral lymphocyte apoptosis and Ai|»mlow 
were measured ex vivo by flow cytometry for all patients. 
Results: CD4 T-helper apoptosis for the EFV and NVP cohorts was 
19.38% ± 2.62% and 23.35% ± 1.51% (mean ± SEM), respectively, 
whereas total lymphocyte A4<m'ow was 27.25% ± 5.05% and 17.04% ± 
2.98%, respectively. Both parameters for each cohort were significantly 
lower (P < 0.05) than that of the HAART-naive patients. The NVP 
cohort exhibited both a significant time-dependent increase in periph-
eral lymphocyte Av|/mlow (P = 0.038) and correlation between T-helper 
apoptosis and Ai|milow (P = 0.0005). These trends were not observed in 
the EFV cohort. 
Conclusions: This study provides evidence that both EFV and NVP 
induce peripheral lymphocyte Ai|imlow in HIV-1-infected patients on 
nonnucleoside reverse transcriptase inhibitor-based HAART, which 
in the case of NVP is sufficient to induce the apoptosis cascade. 
Key Words: efavirenz, nevirapine, peripheral lymphocytes, mito-
chondrial depolarization, apoptosis 
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INTRODUCTION 
Highly active antiretroviral therapy (HAART) is 
currently the only treatment that effectively reduces the 
morbidity and mortality of individuals infected with HIV-1.' 
HAART results in a reduction in plasma viral load with a 
subsequent increase in circulating CD4 T-helper (TH) lym-
phocytes2 4 and decreased lymphocyte apoptosis.5 7 Standard 
HAART regimens typically comprise 2 nucleoside reverse 
transcriptase inhibitors (NRTIs) and either one nonnucleoside 
reverse transcriptase inhibitor (NNRTI) or a protease inhibitor 
(PI). Continuous suppression of viral replication requires long-
term therapy during which patients develop severe side effects. 
Lipodystrophy syndrome (LDS), the result of long-term NRTI 
therapy, is characterized by dyslipidemia, body fat redistribu-
tion, and metabolic abnormalities.8'9 
NRTI-associated LDS is attributed to the mitochondrial 
(mt) toxicity of this drug class,910 which is mediated by the 
inhibition of the mt enzymes DNA polymerase gamma 
(Pol-"/),11'12 adenylate kinase,13 thymidine kinase (TK) type-
2,14 and ADP/ATP translocator.15 The inhibition of P0I-7, the 
enzyme responsible for mitochondrial DNA (mtDNA) rep-
lication, is however the most significant contributor to mt 
toxicity. The in vitro hierarchy of P0I-7 inhibition by NRTIs 
(triphosphorylated) in descending order is as follows: zal-
citabine (ddC) > didanosine (ddl) > stavudine (d4T) > 
lamivudine (3TC) > emtricitabine (FTC) > zidovudine (AZT) > 
abacavir (ABC).12 mtDNA depletion and deletion have been 
observed in vitro in NRTI-treated cell lines16 18 and in vivo in 
fat,19,20 skeletal muscle,21 and liver tissue22 of LDS patients. 
In recent studies, human peripheral lymphocytes exposed 
in vivo23-24 and in vitro25,26 to NRTI-containing HAART also 
exhibited significant mtDNA depletion. Furthermore, reduced 
expression and activity of mtDNA-encoded complexes of the mt 
respiratory chain were observed in NRTI-treated T lympho-
cytes25 and peripheral blood mononuclear cells (PBMCs) of 
LDS patients, respectively.24 Impairment of respiratory chain 
enzyme expression inhibits oxidative phosphorylation,27 with 
possible induction of apoptosis via the mt pathway.28 
Conversely, Pis have been shown to prevent apoptosis, at the 
mt level by preventing collapse of the mt transmembrane 
potential (Aihm).29 The effect of NNRTIs on mitochondria is 
less well documented, although efavirenz (EFV) has been 
reported to induce apoptosis in vitro via the mt pathway in the 
Jurkat cell line and primary T cells of uninfected donors.30 
However, the in vivo effect of the commonly prescribed 
NNRTIs, EFV, and nevirapine (NVP) on patient lymphocyte 
mitochondria remains unknown. We therefore assessed ex vivo 
mt depolarization (At|imlow) and apoptosis in lymphocytes of 
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HIV-1-infected patients who were treated with either EFV or 
NVP as a component of triple-drug HAART, for 4-24 months. 
METHODS 
Study Design and Patient Recruitment 
The study was approved by the University of KwaZulu-
Natal, Biomedical Research Ethics Administration (HI29/04). 
Patients were recruited from an antiretroviral rollout clinic 
at a tertiary-level hospital after obtaining informed consent. 
All patients were black South Africans with HIV-1 infection. 
Thirty-two patients on NNRTI-based HAART were enrolled 
(8 males:24 females). Sixteen HIV-1-infected patients 
(5 males: 11 females) who were HAART naive were recruited 
as control subjects. 
Drug Regimens 
Three HAART regimens are currently prescribed to 
HIV-1-infected patients in South Africa: regimen la: stav-
udine (d4T), lamivudine (3TC), and EFV; regimen lb: d4T, 
3TC, and NVP; and regimen 2: zidovudine (AZT), didanosine 
(ddl), and lopinavir/ritonavir. Only patients on regimen la or 
lb (males:females; 6:6 and 2:18, respectively) were recruited. 
Patients on Pl-based regimens were excluded so as to preclude 
the antiapoptotic effects of the Pis (lopinavir/ritonavir) on 
PBMCs. HAART drugs were dosed as follows: regimen la/lb: 
d4T [30 mg/12 h if body weight (body weight < 60 kg, 40 
mg/12 h if body weight > 60 kg)]; 3TC (150 mg/12 h); and 
EFV (600 mg/24 h)/NVP (200 mg daily for initial 2 weeks, 
followed by 200 mg/12 h). Four of the 32 patients on NNRTI-
based HAART (2 from each regimen) were treated with AZT 
(300 mg/12 h) instead of d4T All HIV-infected patients were 
18 years and older and 50 years and younger. Patients in the 
NNRTI-based HAART group were on therapy for a minimum 
of 4 months and did not have signs and symptoms of LDS. 
Patients with an abnormal liver function profile were excluded. 
Patients with a current diagnosis or undergoing treatment for 
opportunistic infections or malignancy were excluded. All 
patients were on trimethoprim and sulfamethoxazole (160/800 
mg daily) as prophylaxis against Pneumocystis carinii pneu-
monia and Toxoplasma gondii. 
Flow Cytometry Reagents 
Monoclonal anti-human CD4-APC antibody, BD Tri-
TEST CD4-FITC/CD8-PE/CD3-PerCP antibody kit, and JC-1 
MitoScreen kit were from Becton Dickinson (BD Biosci-
ences, San Jose, CA). The Annexin-V-FLUOS kit was 
purchased from Roche Diagnostics GmBH (Penzberg, Ger-
many). Histopaque-1077 and 0.4% trypan blue solution were 
from Sigma-Aldrich (Durban, South Africa). 
Isolation of PBMCs 
All blood specimens were processed for apoptosis 
assays within 6 hours of being drawn. PBMCs were isolated 
from heparinized whole blood by centrifugation on a 
Histopaque-1077 density gradient at 400g for 30 minutes at 
room temperature (RT). Isolated PBMCs were washed twice in 
phosphate buffered saline (PBS) (pH 7.4) (350g for 10 minutes 
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at RT) before cell counting and viability determination via 
trypan blue dye exclusion. 
Flow Cytometric Analysis of Lymphocyte 
Apoptosis and Ai|jm 
Separate aliquots of approximately 1 X 106 PBMCs 
were stained and analyzed for each assay. 
Annexin-V-FLUOS Assay 
Lymphocyte apoptosis was determined by measuring the 
translocation of phosphatidylserine to the outer cell membrane 
surface using Annexin-V-FLUOS. Necrotic cells were distin-
guished from apoptotic cells by staining with propidium iodide.31 
PBMCs were incubated with 100 uT Annexin-V-FLUOS 
reagent and 5 u.L CD4-APC in the dark at RT for 15 minutes. 
JC-1 MitoScreen Assay 
Lymphocyte Aijim was measured flow cytometrically 
with the JC-1 dye as previously reported.32 PBMCs were incu-
bated in 500 (xL JC-1 solution at 37°C (5% C02-humidified 
atmosphere) for 15 minutes. Stained PBMCs were washed 
twice in JC-1 MitoScreen wash buffer (350g for 10 minutes at 
RT). As CD4-APC-positive lymphocyte populations were not 
distinguishable when costained with the JC-1 dye, Ai|im data 
were acquired for total lymphocyte populations only. All flow 
cytometric data were acquired immediately after staining on an 
FACSCalibur flow cytometer with CellQuest PRO v4.0.2 soft-
ware (BD Biosciences). A total of 50,000 PBMC events were 
acquired for each assayed sample. Lymphocytes were gated on 
forward scatter and side scatter parameters to exclude debris 
and nonlymphoid cells using Flow Jo v7.1 software (Tree Star, 
Inc). Lymphocytes were gated on their fluorescent probes for 
the respective assays (Fig. 1). 
CD4 Count and Viral Load Determination 
HIV-1 RNA viral load levels were determined using the 
Nuclisens Easy Q HIV-1 assay (bioMerieux) (assay detection 
limit: 25 copies/mL). CD4 TH absolute counts were evaluated 
flow cytometrically with the BD TriTEST kit on whole blood 
samples (MultiSET v. 1.1.1, BD Biosciences). 
Statistical Analysis 
All statistical analyses were performed using GraphPad 
InStat v3.06 (GraphPad Software, San Diego, CA). Differ-
ences between the control and HAART regimens for lym-
phocyte apoptosis and Ai(/mlow were compared by parametric 
unpaired t tests (2-tailed P value). Viral loads and CD4 TH 
counts were also compared by parametric unpaired t tests 
(1-tailed P value). Differences between total lymphocyte and 
TH apoptosis within each regimen were compared by paired 
t tests. Correlations between lymphocyte apoptosis and 
Ai}im'ow and with the duration of HAART were analyzed with 
Spearman tests. A P value < 0.05 was considered significant 
in all statistical comparisons. 
RESULTS 
Clinical Parameters 
HIV-1 plasma viral loads for all HAART-treated patients 
were below the lower detection limit of the assay and 
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A FL1-H: Annexin-V-FITC 
B FL1-H: JC1 (FL1) 
FIGURE 1. Flow cytometric scatter plots of HIV-1-infected 
patient lymphocytes stained with (A) Annexin-V-FLUOS and 
(B) )C-1 dye. A, Uve, apoptotic, and necrotic lymphocytes were 
gated as live cells: Annexin-V-FITC log FL1-H < 10% Ppl log 
FL3-H < 102; apoptotic cells: Annexin-V-FITC log FL1 -H > 102, 
Ppl log FL3-H < 102; necrotic cells: Annexin-V-FITC log 
FL1-H > 102, Ppl log FL3-H s 102. B, |C-1 dimerizes in 
lymphocytes with an intact A»|im resulting in a higher red 
fluorescence emission detected in the FL2-H channel in 
addition to green fluorescence detected in the FL1 -H channel 
(i). JC-1 remains in monomeric state in lymphocytes with 
a collapsed A»|im and emits only green fluorescence (FL1 -H) (ii). 
Ppl, propidium iodide; FL, fluorescence. 
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significantly lower than that of the HAART-naive cohort (P < 
0.0001). Both regimen la and lb cohorts had significantly 
higher mean CD4 TM counts than the HAART-naive cohort 
(P = 0.014 and P = 0.0008, respectively) (Table 1). 
Apoptosis and A»(imlow 
Mean total lymphocyte apoptosis of the HAART-naive 
cohort was higher than in both regimen 1 a and lb cohorts, with 
only the latter comparison being significant (P = 0.037). Mean 
TM apoptosis of the HAART-naive cohort was significantly 
higher than that of both regimen la and lb cohorts (P = 0.0006 
and P = 0.0003, respectively). In both HAART cohorts, mean 
total lymphocyte apoptosis was significantly higher than mean 
Tii apoptosis (P = 0.026 and P - 0.001, respectively), whereas 
these parameters correlated significantly to each other in both 
regimens la (P = 0.035) and lb (P = 0.0004). This correlation 
however was not observed in the 1 lAART-naive cohort (P = 
0.141). Conversely, mean TH apoptosis of the HAART-naive 
cohort was higher than mean total lymphocyte apoptosis, 
although this difference was not significant either (P = 0.330) 
(Table 2). In addition, differences between the 2 HAART 
cohorts with respect to total lymphocyte and T„ apoptosis 
were also tested, with neither of these comparisons being 
significant. 
Mean total lymphocyte Ai|imlmv of the HAART-naive 
cohort was significantly higher than that of both cohorts la and 
lb {P = 0.017 and P < 0.0001, respectively). Moreover, 
mean lymphocyte Ai|»m'TOV in the regimen la cohort was 
approximately 1.5 times higher than in the regimen lb cohort, 
although this difference was not significant (P = 0.072). In 
comparison to the HAART-naive cohort, both cohorts la and 
lb notably exhibited reductions in mean total lymphocyte 
Ai)W"" in relation to their respective mean total lymphocyte 
apoptosis (Table 2). The significance of these changes was 
determined by testing the degree of correlation between total 
lymphocyte Aijim'"* and apoptosis for all 3 groups. The only 
statistically significant correlation was observed between T,i 
apoptosis and lymphocyte A(J>m'"w for the regimen lb cohort 
[P = 0.039; /• = 0.464, Fig. 2A). Interestingly, the correlation 
between TM apoptosis and lymphocyte Aijim
1"" in the 11AART-
naive cohort was not significant (P = 0.105). 
Correlation of Apoptosis and Au>mlow With 
Duration of HAART 
Regimen lb (NVP) patients demonstrated a significant 
time-dependent increase in lymphocyte A^m1"" (Fig. 2B, P = 
0.0005; r - 0.704). Such a correlation was not observed for 
regimen la (EFV) patients. Furthermore, total and T,| lym-
phocyte apoptosis correlations against treatment duration were 
not significant in either regimen la or lb cohorts. 
Patients in each cohort were stratified into I of 4 sub-
categories, according to their respective durations on HAART 
up to the point of recruitment (Table 3). Statistical differences 
between each cohort for the corresponding subcategories with 
regard to lymphocyte apoptosis and Ai|rnikm were tested. 
Between the initial 4 6 months of therapy, both mean total 
lymphocyte and TM apoptosis in the regimen la (EFV) cohort 
were significantly lower than that of the regimen lb (NVP) 
cohort (P = 0.004 and P = 0.027, respectively). 
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TABLE 1. Clinical Parameters of HAART-Naive and HAART-Treated HIV-1-Infected Patients 
HAART-Naive HIV-1-Infected 
Patients (n = 16) 
CD4+ TH count (cells/|xL) 144 ± 23.25 
Plasma viral load (logio copies/mL) 4.40 ± 0.24 
Duration on HAART (months) — 
All values are reported as mean ± SEM. 
*F = 0.014; t/> = 0.0008; %P < 0.0001 (Difference from HAART-naive cohort). 
HAART-Treated HIV-1-Infected Patients 
Regimen l a (n = 12) Regimen l b (n = 20) 
254 ± 45.32* 315 ± 40.70t 
1.06 ± 0.02 | 1.22 ± O.lOt 
12 ± 1.73 9 ± 1.11 
However, during this period, mean total lymphocyte Ai(imlow in 
the regimen la (EFV) cohort was nearly 4 times greater than 
that of the regimen lb (NVP) cohort (P = 0.006). Furthermore, 
mean TH apoptosis of the regimen 1 a (EFV) cohort, during 
months 13-18, was approximately 1.8 times lower than that of 
the regimen lb (NVP) cohort for the same period (P = 0.019). 
Comparisons between the other subcategories were not statis-
tically significant. 
In addition, the subcategories within each regimen were 
compared against each other for the respective assays. The 
regimen 1 a (EFV) cohort exhibited significant time-dependent 
increases in both total lymphocyte and TH apoptosis para-
meters up to only the 12th month of treatment (P = 0.026 and 
P = 0.029, respectively). This was the only significant trend 
noted for regimen 1 a, whereas no significant trends in the total 
lymphocyte and TH apoptosis parameters were observed for 
regimen lb. In regimen lb, however, the only significant trend 
observed was a time-dependent increase in lymphocyte 
AiJimlow between 4 and 18 months (4-6 months < 7-12 
months and 4-6 months < 13-18 months) of treatment (Table 3 
and Fig. 2B). Conversely, regimen 1 a patients exhibited a non-
significant time-dependent decrease in lymphocyte Ai(rmlow up 
to 18 months of treatment. Notably, total lymphocyte apoptosis 
was consistently higher than TH apoptosis in all subgroups of 
both regimens, a finding similar to the comparison of the means 
of these parameters (Table 1). 
DISCUSSION 
Elevated TH and cytotoxic T-lymphocyte apoptosis is the 
primary mechanism of HIV-1-induced T-lymphocyte de-
pletion33 35; however, the majority of TH that are committed 
to apoptosis are uninfected bystander cells.36 Bystander TH 
apoptosis is primarily mediated by Fas ligand-37 40 and/or 
tumor necrosis factor-related apoptosis-inducing ligand-
dependent41 activation-induced cell death, whereas infected 
TH cells are spared from autonomous Fas- or TNF-related 
apoptosis-inducing ligand-mediated apoptosis via the inhibi-
tion of apoptosis signal-regulating kinase-1 by Nef protein.42 
In the HAART-naive cohort, mean TH apoptosis was higher 
than, although not significantly different from total lympho-
cyte apoptosis. Significant reductions in TH apoptosis below 
total lymphocyte apoptosis and that of HAART-naive TH 
apoptosis in both treatment cohorts suggest the reduction of 
apoptosis in bystander and directly infected TH cells by 
HAART (Table 2). This is further supported by the absence 
of detectable plasma virus and significantly higher peripheral 
TH counts in patients of both treatment cohorts. 
Furthermore, the loss of Ai|mi is a crucial event in TH 
apoptosis during HIV-1 infection.43 A mean lymphocyte 
AiJim'ow of ~45% in our HAART-naive cohort that was sig-
nificantly higher than in both HAART cohorts corresponds 
with this finding. However, the lack of a significant correlation 
between lymphocyte apoptosis and lymphocyte Ai|jmlow in 
the HAART-naive cohort seemed paradoxical. This could be 
explained by the effect of the soluble HIV-1 viral protein R on 
mitochondria, whereby it promotes the loss of Ai|im in both 
infected and uninfected cells by inducing the opening of the mt 
permeability transition pore complex.44 Viral protein R, how-
ever, does not induce the release of apoptosis-inducing factor 
from the permeabilized mitochondrion into the cytoplasm.45 
The subsequent translocation of phosphatidylserine from the 
cytoplasmic to the extracellular plasma membrane surface, as 
catalyzed by apoptosis-inducing factor, would be reduced and 
thus also the binding of Annexin-V to the depolarized 
lymphocyte. 
TABLE 2. Lymphocyte Apoptosis and Ai|»mlow Data for HAART-Naive and HAART-Treated 
HIV-1-Infected Patients 
Total lymphocyte apoptosis (%) 
CD4+ TH apoptosis (%) 
Total lymphocyte At|mil0"' (%) 
HAART-Naive HIV-1-Infected 
Patients (n = 16) 
35.67 ± 2.42cpT 
39.53 ± 4.04<pT 
44.22 ± 4.36 
HAART-Treated HIV-1 
Regimen l a (n = 12) 
27.45 ± 4.04§A 
19.38 ± 2.62*§A 
27.25 ± 5.05* 
-Infected Patients 
Regimen l b (n = 20) 
28.77 ± 2.08#t© 
23.35 ± 1.51**10« 
17.04 ± 2 .98H* 
All values are reported as mean ± SEM. 
ttP = 0.037; *P = 0.0006; **P = 0.0003; $P = 0.017; ttP < 0.0001 (Difference from HAART-naive cohort). 
•P = 0.039 (Correlation between control T„ apoptosis and Ai|imlow). 
tpP = 0.330; §P = 0.026; \P = 0.001 (Difference between total and TH lymphocyte apoptosis). 
rp = 0.141; A/3 = 0.035; 9P= 0.0004 (Correlation between total and TH lymphocyte apoptosis). 
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We report reduced but persistent spontaneous peripheral 
lymphocyte apoptosis and Ai|;mlow during HAART in our 
study, with similar levels of lymphocyte apoptosis reported in 
previous in vivo studies.46,47 TH lymphocyte apoptosis was 
consistently lower than total lymphocyte apoptosis in both 
HAART cohorts, suggesting that other lymphocyte subsets, 
such as CD8 cytotoxic T lymphocytes and B cells, were 
concurrently undergoing apoptosis. de Oliveira Pinto et al46 
noted a significant persistence of lymphocyte apoptosis in over 
70% of their chronically treated (up to 55 months) HAART 
patients. The persistence of lymphocyte apoptosis in this 
cohort may be attributed to mt toxicity via NRTl-induced (d4T 
and 3TC) mtDNA depletion, which is however predominant 
during chronic therapy.23'24,48 NRTI-induced lymphocyte 
mtDNA depletion is, however, most prevalent in LDS patients 
compared with patients without LDS,24'49 the latter which 
comprised our study subjects. Furthermore, PBMCs (lym-
phocytes and monocytes) intrinsically lack cytosolic TK1 but 
retain mt expression of TK2.27 Hence, in peripheral lym-
phocytes, the initial monophosphorylation step of AZT and 
d4T (thymidine analogues), as catalyzed by TK1/2, is local-
ized to the mitochondrion, thus ultimately restricting the 
incorporation of these triphosphorylated NRTIs into nuclear 
DNA. In addition, the triphosphates of d4T and 3TC are poor 
inhibitors of a, p, and s nuclear DNA polymerases.12 When 
analyzed as a separate group, the lymphocyte apoptosis and 
Ai|)mlow parameters of the 4 AZT-treated patients were not sta-
tistically different from those of cohorts la and lb (data not 
shown). These factors therefore preclude the induction of 
peripheral lymphocyte apoptosis in our acutely treated subjects 
via NRTI-induced mtDNA and nuclear DNA damage. 
Mean lymphocyte Ai|imlow was significantly higher in 
the regimen la cohort (EFV) than in the regimen lb cohort 
(NVP); however, we noted a nonsignificant time-dependent 
decrease in A4imlow lymphocytes in the former between 4 and 
18 months of treatment but a significant time-dependent 
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TABLE 3. Analysis of Lymphocyte Apoptosis and Ai|;mlow According to Duration of HAART 
Annexin-V-FLUOS Assay 
Duration Total Lymphocyte CD4+ TH 





4-6 months (n = 3) 
7-12 months (n = 5) 
13-18 months (n = 2) 
19-24 months (n = 2) 
;gimen lb 
4-6 months (n = 10) 
7-12 months (n = 7) 
13-18 months (n = 2) 
19-24 months (n = 1) 
5 ± 0.3 
10 ± 1.0 
17 ± 1.0 
21 ± 1.0 
5 ± 0.2 
10 ± 0.8 
15 ± 1.0 
24 
11.16 ± 3.72*1 
31.66 ± 4.611 
34.96 ± 8.27 
33.86 ± 14.63 
29.37 ± 2.45* 
28.19 ± 4.50 
34.44 ± 1 . 1 9 
15.45 
10.78 ± 5.05t|| 
25.41 ± 2.69|| 
15.42 ± 1.39§ 
21.18 ± 8.94 
23.29 ± 2.24t 
23.49 ± 2.43 
28.35 ± 1.18§ 
13.01 
35.28 ± 12.03* 
29.05 ± 9.31 
13.52 ± 2.40 
24.44 ± 8.75 
9.11 ± 2.66| 
21.21 ± 5.02# 
33.12 ± 6.61** 
35.01 
All values are reported as mean ± SEM. 
*P = 0.004; tP = 0.027; $P = 0.006; §P - 0.019 (Difference between regimens la and lb). 
%P = 0.026; lP - 0.029 (Difference between 4 and 6 months and 7 and 12 months of regimen 
UP = 0.036; **P = 0.005 (Difference from months 4 to 6 of treatment). 
la treatment). 
increase in At)/mlow lymphocytes in the latter group. Further-
more, there was a positive significant correlation between 
TH apoptosis and lymphocyte At(im
low in the regimen lb cohort 
(Fig. 2A), which suggests that NVP induces apoptosis in 
peripheral lymphocytes via the collapse of A4<m in vivo at 
therapeutic concentrations. Interestingly, we noted that neither 
total lymphocyte nor TH apoptosis correlated with lymphocyte 
Ai)»mlow in the regimen la cohort. Although the plasma con-
centrations of EFV achieved during therapy may be sufficient to 
disrupt A\\im in peripheral lymphocytes, only a small per-
centage of these cells may develop mt permeabilization with 
the subsequent release of cytochrome c and apoptosome for-
mation, thereby committing them to apoptosis. In addition, 
immune activation has been shown to persist, although at 
a lower level, during HAART.49 Activated lymphocytes express 
high levels of surface Fas and Fas ligand, rendering them sus-
ceptible to apoptosis by activation-induced cell death. Apop-
tosis in these cells may occur via the type 1 Fas pathway,50 
which bypasses mitochondria. These 2 factors provide a plau-
sible explanation for the lack of correlation between lym-
phocyte At|/mlow and apoptosis in the EFV cohort, de Oliveira 
Pinto et al46 reported the highest levels of apoptosis in periph-
eral lymphocytes of HAART patients following Fas receptor 
ligation in vitro, a finding that supports our theory. 
In contrast to our findings for EFV-treated patients, Pilon 
et al30 reported concentration-dependent increases in apoptosis 
and A(J»m,ow in EFV-treated Jurkat cells and PBMCs in vitro. 
However, the concentrations of EFV assayed by Pilon et al 
exceed the peak plasma levels achieved by a daily dose of 
600 mg EFV (Cmin = 5.6 \iM; Cmax = 12.9 uM). Furthermore, 
in circulation, EFV is 99% bound to plasma albumin (com-
pared with 60% for NVP), thereby reducing the availability of 
EFV to peripheral-circulating lymphocytes. 
Uncoupling proteins are proton transporters, present in 
the inner mt membrane, that mediate a regulated dissipation of 
the Aihm." Rodriguez de la Concepcion et al52 reported a sig-
nificant induction of uncoupling protein 1 expression in brown 
adipocytes mediated by both NVP and d4T in vitro, with the 
degree of induction by NVP being significantly higher than 
that of d4T. The collapse in PBMC At|;m could be mediated by 
NVP in vivo, via the induction of other uncoupling protein 
isoforms in PBMCs. This effect could be exacerbated dur-
ing cotreatment with d4T, as in the case with our regimen 
lb-treated patients. A decrease in ATP synthesis via oxidative 
phosphorylation will lead to an increase in At|;mlow. 
Notably, lymphocyte Avl»m,ow in EFV-treated patients 
was approximately 4 times higher than in NVP-treated patients 
within the 4-6 months period of treatment. However, this dif-
ference could be attributed to the patient numbers of the EFV 
cohort being considerably lower than that of the NVP cohort at 
this period of treatment. It must be noted that the varying 
degrees of toxicity in patients treated with EFV and NVP may 
be attributed to interpatient variations in the biotransformation 
of these drugs, due to polymorphic variants of the hepatic 
cytochrome P450 2B6 (CYP 2B6) gene.
53'54 The influence of 
NRTIs sulfamethoxazole and trimethoprim on the induction or 
inhibition of hepatic CYP 2B6 is negligible because the NRTIs 
are not metabolized by the hepatic CYP450 system, whereas 
trimethoprim and sulfamethoxazole are selective inhibitors 
of only CYP 2C8 and 2C9, respectively, at concentrations 
achievable in vivo.55 
This pilot study provides evidence that the NNRTIs, 
EFV, and NVP are potential inducers of mt toxicity at 
concentrations achieved in vivo during clinical therapy. This 
mechanism of toxicity has important implications in the etiol-
ogy of NNRTI-induced adverse effects including central ner-
vous system toxicity, Stevens-Johnson syndrome, and toxic 
epidermal necrolysis. Because neither EFV nor NVP are inhi-
bitors of P0I-7, the exact mechanism by which EFV and NVP 
induce mt toxicity requires further investigation. The foremost 
limitation of this study is that the in vivo toxicity of each 
NNRTI drug could not be determined alone, as triple-drug 
therapy is now standard of care for the treatment of HIV-1 
infection. We have however provided plausible explanations 
that exclude the involvement of NRTIs in the induction of 
lymphocyte apoptosis and mt depolarization in our treatment 
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groups. Furthermore, because both EFV and NVP are exten-
sively metabolized by the CYP450 system, the time-dependent 
lymphocyte Ai|jm trends could indeed be influenced by the 
polymorphic variability of this enzyme system in individual 
patients. Finally, patients on EFV showed increased mt toxicity 
as compared with patients on NVP. This may indicate a syn-
ergism between d4T and NVP in mt toxicity induction and 
warrants further investigation. 
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CONCLUSION 
The mechanisms by which the NRTIs and Pis modulate lymphocyte mitochondrial function, both 
in vivo and in vitro, are documented extensively in the literature. By contrast, literature pertaining 
to the potential of the NNRTIs to mediate lymphocyte mitochondrial toxicity is scarce. The data 
from this novel pilot study strongly implicates the NNRTIs, EFV and NVP, in promoting 
lymphocyte A\|/mlow at concentrations achieved in vivo during clinical management of HIV-1 
infected patients. This is supported by the persistence of lymphocyte A\|/mlow in both the EFV and 
NVP patient cohorts, in the absence of detectable viral replication. Furthermore this study 
demonstrates that NVP promotes lymphocyte apoptosis through the induction of lymphocyte 
A\|/mlow. Evidence in support of this includes the significant direct correlation between CD4+ THL 
apoptosis and A\|/mlow and a significant therapy duration-dependant increase in lymphocyte 
A\|/mlow in the NVP patient cohort. 
These findings have two important clinical implications. Firstly, the NNRTIs, especially NVP, 
may exacerbate the mitochondrial toxicity of NRTIs and thereby hasten onset of LDS in patients 
treated with these drug class combinations. Secondly, considering the mechanisms of HIV-1 -
mediated lymphocyte mitochondrial toxicity, the NNRTIs may inadvertently promote the decline 
of CD4+ THL cells in patients that develop NNRTI-resistant viral mutants as a result of poor 
adherence to HAART. In contrast to the NRTIs, NNRTI drugs do not inhibit mt Pol-y, which 
suggests that the NNRTIs employ a different mechanism of mt toxicity to the NRTIs. Previous 
studies reported the induction of mt UCP expression by NVP. This presents a plausible 
explanation of the observed increase in NVP-induced collapse of lymphocyte Aym in this study, 
however further investigations into this potential mechanism of action are now warranted. 
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